Dr. Sherif joined Oculis as Chief Executive Officer in 2017 from Novartis where he served as Entrepreneur in Residence at the Novartis Venture Fund. Since his arrival, the company raised over $100M USD, two successful Phase 2b trials were completed with OCS-01, a positive end-of-phase 2 meeting was conducted with the FDA propelling OCS-01 into Phase 3 for two distinct indications, the OPTIREACH® formulation technology was validated for both: the back- and the front-of-the-eye, and OCS-02, an antibody fragment anti-TNF alpha, was in-licensed from Novartis.
Prior to this, he held senior global positions in both Alcon, where he was President of Europe, Middle East and Africa, and Novartis, where he served as President of Novartis Pharmaceuticals, Canada. Dr. Sherif joined Novartis Pharmaceuticals in 2002 and has also held roles as Head of Transplant and Infectious Disease for Latin America, and President of the Novartis Vaccines and Diagnostics Division for Latin America. During his tenure in Canada and in Europe, he held several Chairman and Co-chair positions such as Vice Chairman for the Innovative Medicine Canada Association in Ottawa, Chairman of In-Vivo Montreal and Chairman of the Board Ophthalmic Surgery and Vision Care at Eucomed, Brussels.
Prior to Novartis, Dr. Sherif worked for several pharmaceutical companies, holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr. Sherif is a medical doctor by training, and also has an MBA from IMD and a Specialized Master’s Degree in Medical Management.
Gudrun M. Asgrimsdottir joined Oculis in 2010 from GlaxoSmithKline in Reykjavik where she served as Business Unit Manager. Since joining Oculis, Ms. Asgrimsdottir has had management roles, currently holding the position of VP Pharmaceutical Development. Ms. Asgrimsdottir received a M.Sc. degree in pharmacy from the University of Iceland in 1997. Upon completing her studies, Ms. Asgrimsdottir joined the R&D department of Omega Farma ehf. where she was primarily responsible for analytical method development. In year 2000 she worked for GlaxoWellcome in the UK. Ms. Asgrimsdottir had the role of a clinical pharmacist in the UK for 4 years and did a diploma in hospital pharmacy from University of London in 2004. Ms. Asgrimsdottir is a co-author of 8 published papers in peer reviewed journals.
Dr. Chang brings to Oculis more than 20 years of global experience in medical and regulatory affairs, clinical development, health economics and market access. She joins Oculis from Novartis where she spent the last 13 years in various senior leadership roles in both the US and China. At Novartis, Dr. Chang led the Global Medical Affairs team where she provided strategic oversight for the ophthalmology portfolio, including retinal, Gene Therapy and ocular surface disease.
Before this Dr. Chang served as Head of Clinical Development & Medical Regulatory Affairs in North America at Alcon where she oversaw all strategic, medical, and scientific aspects of clinical development. She was also Chief Medical Officer and Vice President of Medical Affairs in Greater China at Novartis where she established medical organization and provided strategic insights regarding medical, clinical and industry trends and growth opportunities in China.
Prior to Novartis, Dr. Chang held various senior roles in health economics, strategic marketing and clinical development at key global pharmaceutical companies including Bayer, Aventis, Johnson & Johnson and Abbott Laboratories.
Dr. Chang gained her Doctor of Medicine from Wuhan University and has further completed the post-doctoral fellowship in Johns Hopkins and a Ph.D. at the University of Maryland Baltimore.
Mr. Jóhannesson joined Oculis in 2015 from Straumur Investment Bank where he served as Managing Director Corporate Finance. Prior to joining Straumur in 2015, he worked for Islandsbanki, and its predecessor Glitnir Bank, in Corporate Finance and Business Development. He has broad sector experience, having managed and advised on transactions within multiple industries, including pharmaceuticals, venture capital, energy, financials, and various manufacturing industries. Mr. Jóhannesson’s transaction experience includes, IPOs, private placements, M&A and restructurings. Mr. Jóhannesson has a B.Sc. in Industrial Engineering from the University of Iceland, an M.Phil in Management Science from the University of Cambridge and is a certified securities broker in Iceland.
Mr. Maderi joined Oculis in 2021, from Santen, a key player in Ophthalmology, where he was Head of Quality EMEA. Prior to Santen, he held several Global Quality Assurance and Management position from the Biotech, Pharma and Devices industries. He brings in expertise covering product life cycle from R&D to commercialization. Mr. Maderi worked at GSK, Ferring and BBraun where he oversaw and led quality over product development, commercial regions and manufacturing for sterile and non-sterile products. Mr. Maderi received an executive MBA from the University of Geneva and an MSc in Chemical Engineering from EPFL.
Dr. Pilotaz joins Oculis with more than 20 years’ experience in innovation of global sterile health products in both pharmaceutical and medical device industries, including 15 years in the Ophthalmology sector specifically. Most recently, he was Senior Director and Head of CMC and Pharmaceutical Operations at Nicox S.A. in charge of several outstanding ophthalmic development projects for the USA market. He has previously worked for Becton Dickinson and Laboratoires Thea with multiple incremental leadership positions in the R&D field.
Dr. Pilotaz completed a doctorate degree in pharmacy from the Grenoble school of pharmacy and he has a noteworthy experience in both intellectual property, project management, device design and marketing. He has an extensive track record in sterile drug design, development, industrialization and registration. He is co-author in 5 formulation patents for topical ophthalmic drugs and successfully contributed to multiple drugs commercialized in both Europe and USA.